Genetic Polymorphisms in the m -Opioid Receptor Gene and Breast Cancer Survival

Morphine and Metastasis

Volumn , Issue , 2013, Pages 95-112

  Bortsov, Andrey V ^a   Millikan, Robert C ^b   Belfer, Inna ^c   Boortz Marx, Richard L ^a   Arora, Harendra ^a   Mc Lean, Samuel A ^a  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Allele; Breast cancer; Cancer survival; Endorphins; Exon; Intron; Linkage disequilibrium; Opioid receptor; Single nucleotide polymorphism

Indexed keywords

EID: 84956483930     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-94-007-5678-6_7     Document Type: Chapter

References (55)

1. Afsharimani B, Cabot P, Parat MO (2011) Morphine and tumor growth and metastasis. Cancer Metastasis Rev 30(2):225-238
2. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2):263-265
3. Bart G, LaForge KS, Borg L, Lilly C, Ho A, Kreek MJ (2006) Altered levels of basal cortisol in healthy subjects with a 118G allele in exon 1 of the Mu opioid receptor gene. Neuropsychopharmacology 31(10):2313-2317
4. Ben-Eliyahu S (2003) The promotion of tumor metastasis by surgery and stress: immunological basis and implications for psychoneuroimmunology. Brain Behav Immun 17(Suppl 1):S27-36
5. Beyer A, Koch T, Schroder H, Schulz S, Hollt V (2004) Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 89(3):553-560
6. Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ (2008) Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology 109(2):180-187
7. Boehncke S, Hardt K, Schadendorf D, Henschler R, Boehncke WH, Duthey B (2011) Endogenous mu-opioid peptides modulate immune response towards malignant melanoma. Exp Dermatol 20(1):24-28
8. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L (1998) Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 95(16):9608-9613
9. Bortsov AV, Millikan RC, Belfer I, Boortz-Marx RL, Arora H, McLean SA (2012) Mu-opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology 116(4):896-902
10. Campa D, Gioia A, Tomei A, Poli P, Barale R (2008) Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 83(4):559-566
11. Cata JP, Gottumukkala V, Sessler DI (2011) How regional analgesia might reduce postoperative cancer recurrence. Eur J Pain Suppl 5(2):345-355
12. Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B (2006) Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 105(2):334-337
13. Dietrich K, Schned A, Fortuny J, Heaney J, Marsit C, Kelsey KT, Karagas MR (2009) Glucocorticoid therapy and risk of bladder cancer. Br J Cancer 101(8):1316-1320
14. Durieux ME (2009) Does anesthetic management affect cancer outcome. APSF Newsl 23:49-51
15. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI (2006) Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology 105(4):660-664
16. Farooqui M, Li Y, Rogers T, Poonawala T, Griffin RJ, Song CW, Gupta K (2007) COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer 97(11):1523-1531
17. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M (2002) The structure of haplotype blocks in the human genome. Science 296(5576):2225
18. Gottschalk A, Ford JG, Regelin CC, You J, Mascha EJ, Sessler DI, Durieux ME, Nemergut EC (2010) Association between epidural analgesia and cancer recurrence after colorectal cancer surgery. Anesthesiology 113(1):27-34
19. Grann V, Troxel AB, Zojwalla N, Hershman D, Glied SA, Jacobson JS (2006) Regional and racial disparities in breast cancer-specific mortality. Soc Sci Med 62(2):337-347
20. Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D, Hebbel RP (2002) Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 62(15):4491-4498
21. Hayashida M, Nagashima M, Satoh Y, Katoh R, Tagami M, Ide S, Kasai S, Nishizawa D, Ogai Y, Hasegawa J, Komatsu H, Sora I, Fukuda K, Koga H, Hanaoka K, Ikeda K (2008) Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics 9(11):1605-1616
22. Hernandez-Avila CA, Covault J, Wand G, Zhang H, Gelernter J, Kranzler HR (2007) Population-specific effects of the Asn40Asp polymorphism at the mu-opioid receptor gene (OPRM1) on HPA-axis activation. Pharmacogenet Genomics 17(12):1031-1038
23. Holmes L Jr, Opara F, Hossain J (2010) A five-year breast cancer-specific survival disadvantage of African American women. Afr J Reprod Health 14(3):195-200
24. Huang P, Chen C, Mague SD, Blendy JA, Liu-Chen LY (2012) A common single nucleotide polymorphism A118G of the mu opioid receptor alters its N-glycosylation and protein stability. Biochem J 441(1):379-386
25. Ide S, Han W, Kasai S, Hata H, Sora I, Ikeda K (2005) Characterization of the 3' untranslated region of the human mu-opioid receptor (MOR-1) mRNA. Gene 364:139-145
26. Kleinbaum DG, Klein M (2005) Survival analysis: a self-learning text. Springer, New York
27. Kreek MJ, Bart G, Lilly C, LaForge KS, Nielsen DA (2005) Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 57(1):1-26
28. Kroslak T, Laforge KS, Gianotti RJ, Ho A, Nielsen DA, Kreek MJ (2007) The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem 103(1):77-87
29. Lee HJ, Lee JH, Lee EO, Kim KH, Lee KS, Lee CH, Nam DW, Kim SH, Ahn KS (2009) Substance P and beta endorphin mediate electroacupuncture induced analgesic activity in mouse cancer pain model. Acupunct Electrother Res 34(1-2):27-40
30. Levran O, Awolesi O, Linzy S, Adelson M, Kreek MJ (2011) Haplotype block structure of the genomic region of the mu opioid receptor gene. J Hum Genet 56(2):147-155
31. Mathew B, Lennon FE, Siegler J, Mirzapoiazova T, Mambetsariev N, Sammani S, Gerhold LM, LaRiviere PJ, Chen CT, Garcia JG, Salgia R, Moss J, Singleton PA (2011) The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg 112(3):558-567
32. Maynard C, Lowy E, McDonell M, Fihn SD (2008) Cause of death in Washington state veterans hospitalized with acute coronary syndromes in the veterans health administration. Population Health Metrics 6(1):3
33. NDI User’s Guide (2010) CDC/National Center for Health Statistics. http://www.cdc.gov/nchs/data_access/ndi/ndi_user_guide.htm. Accessed May 9 2010
34. O’Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC (2010) Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 16(24):6100-6110
35. Pang GS, Wang J, Wang Z, Goh C, Lee CG (2009) The G allele of SNP E1/A118G at the mu-opioid receptor gene locus shows genomic evidence of recent positive selection. Pharmacogenomics 10(7):1101-1109
36. Poonawala T, Levay-Young BK, Hebbel RP, Gupta K (2005) Opioids heal ischemic wounds in the rat. Wound Repair Regen 13(2):165-174
37. Ray R, Ruparel K, Newberg A, Wileyto EP, Loughead JW, Divgi C, Blendy JA, Logan J, Zubieta JK, Lerman C (2011) Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci U S A 108(22):9268-9273
38. Rich-Edwards JW, Corsano KA, Stampfer MJ (1994) Test of the national death index and Equifax nationwide death search. Am J Epidemiol 140(11):1016-1019
39. Rogot E, Sorlie P, Johnson NJ (1986) Probabilistic methods in matching census samples to the National Death Index. J Chronic Dis 39(9):719-734
40. Romberg RR, Olofsen E, Bijl H, Taschner PE, Teppema LJ, Sarton EY, van Kleef JW, Dahan A (2005) Polymorphism of mu-opioid receptor gene (OPRM1:c.118A > G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology 102(3):522-530
41. Roy S, Barke RA, Loh HH (1998) MU-opioid receptor-knockout mice: role of [mu]-opioid receptor in morphine mediated immune functions. Molecular brain research 61(1-2):190-194
42. Roy S, Wang J, Kelschenbach J, Koodie L, Martin J (2006) Modulation of immune function by morphine: implications for susceptibility to infection. J Neuroimmune Pharmacol 1(1):77-89
43. Roy S, Ninkovic J, Banerjee S, Charboneau RG, Das S, Dutta R, Kirchner VA, Koodie L, Ma J, Meng J (2011) Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J Neuroimmune Pharmacol 6(4):442-65
44. Salanti G, Amountza G, Ntzani EE, Ioannidis JP (2005) Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet 13(7):840-848
45. Shabalina SA, Zaykin DV, Gris P, Ogurtsov AY, Gauthier J, Shibata K, Tchivileva IE, Belfer I, Mishra B, Kiselycznyk C, Wallace MR, Staud R, Spiridonov NA, Max MB, Goldman D, Fillingim RB, Maixner W, Diatchenko L (2009) Expansion of the human mu-opioid receptor gene architecture: novel functional variants. Hum Mol Genet 18(6):1037-1051
46. Singleton PA, Moss J (2010) Effect of perioperative opioids on cancer recurrence: a hypothesis. Future Oncol 6(8):1237-1242
47. Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J (2006) Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Microvasc Res 72(1-2):3-11
48. Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, Buchser E, Catala E, Bryce DA, Coyne PJ, Pool GE (2002) Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 20(19):4040-4049
49. Szabo I, Rojavin M, Bussiere JL, Eisenstein TK, Adler MW, Rogers TJ (1993) Suppression of peritoneal macrophage phagocytosis of Candida albicans by opioids. J Pharmacol Exp Ther 267(2):703-706
50. Tsui BCH, Rashiq S, Schopflocher D, Murtha A, Broemling S, Pillay J, Finucane BT (2010) Epidural anesthesia and cancer recurrence rates after radical prostatectomy. Can J Anesth/J Can D’anesth 57(2):107-112
51. Waldhoer M, Bartlett SE, Whistler JL (2004) Opioid receptors. Annu Rev Biochem 73:953-990
52. Wang J, Barke RA, Ma J, Charboneau R, Roy S (2008) Opiate abuse, innate immunity, and bacterial infectious diseases. Arch Immunol Ther Exp 56(5):299-309
53. Wang YJ, Huang P, Ung A, Blendy JA, Liu-Chen LY (2012) Reduced expression of the mu opioid receptor in some, but not all, brain regions in mice with Oprm1 A112G. Neuroscience 205:178-184
54. Xu J, Xu M, Hurd YL, Pasternak GW, Pan YX (2009) Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene. J Neurochem 108(4):962-972
55. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W (2005) Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 280(38):32618-32624